CEACAM5 and neoplasm: Compared with serum tumor biomarkers CA24-2, CA19-9, CA72-4, and CEA in CRCs, CDH3 exhibited superior potential as a serum biomarker for monitoring chemotherapy response in distant metastatic CRCs.